Description
BAM15 (2-fluorophenyl-hydrazone derivative) is a mitochondrial proton-channel uncoupler that was developed in the 2010s as a preclinical compound for investigating obesity and metabolic diseases. Mechanistically BAM15 acts like the older DNP: it makes the inner mitochondrial membrane permeable to protons and thereby uncouples the respiratory chain from ATP synthesis.
Per study reports this means: energy from nutrient oxidation is released as heat instead of converted to ATP. The body has to oxidize more substrate to meet ATP demand - leading directly to increased lipolysis and fatty acid oxidation. In mouse studies (Alexopoulos et al 2020, Nature Communications) BAM15 significantly reduced fat mass without loss of muscle mass or body core temperature rise.
The decisive advantage over DNP: BAM15 is about 7x more potent per mole and has a much larger safety window. While DNP completely inhibits the respiratory chain at small overdoses (which explains the toxic hyperthermia cases), BAM15 shows no respiratory inhibition up to 30-fold effective doses in available studies.
A second important property: BAM15 activates AMPK via ATP depletion. This brings additional mechanisms into play - glucose uptake, fatty acid oxidation, insulin sensitivity. In mouse studies BAM15 improved the entire metabolic syndrome profile.
Pharmacokinetically orally bioavailable. Human studies haven’t been published in significant volume - BAM15 remains a preclinical compound today.
You can order BAM15 as oral capsules in one bottle with 50mg per capsule.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
BAM15 sits in the mid range of the risk scale. As a mitochondrial uncoupler the compound has a substantially larger safety window than the older DNP in available studies, but a broad human data base is missing.
Documented in studies and the literature:
- Raised metabolic rate: the uncoupling mechanism releases energy as heat and increases substrate demand - thermogenic activity is part of the mechanism itself.
- Larger safety window than DNP: in available studies BAM15 shows no respiratory inhibition up to 30-fold the effective dose, unlike DNP.
- Hydration and electrolytes: because of the elevated thermogenic activity, monitoring is recommended in the literature, even though less pronounced than under DNP.
- Limited human data: human studies have not been published in significant volume, and BAM15 remains a preclinical compound.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice - Nature Communications 2020, Alexopoulos et al: gold-standard study on obesity and insulin resistance in an animal model.
- Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane - Molecular Metabolism 2014, Kenwood et al: original characterization study, documents the mechanism of BAM15 without plasma membrane depolarization.
- BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control - EMBO Molecular Medicine 2020, Axelrod et al: animal study on weight regulation and glycemic control, documents oral availability.
- BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases - Frontiers in Endocrinology 2023, Zhang et al: recent review of the mechanism and investigated indications.
